Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Glioblastoma Institute
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Brain Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Brain Cancer

Expert Opinion / Cases · February 01, 2022

Treatment of Primary CNS Lymphoma Refractory to High-Dose Methotrexate

L. Gonzalez Castro MD, PhD

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

L. Gonzalez Castro MD, PhD

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • alluru raju

    Feb 02, 2022

    As there is progression of the disease  with HD MTX She can be given Radiation along with steroids.

  • Amir Anvari

    Feb 04, 2022

    Unfortiantly the patient has poor prognosis.my recommendation in radiotherapy whole brain 45 to 50 GY in 25 to 30  fraction

  • Serkan Akin

    Feb 08, 2022

    She is too young for RT. Side effects of RT such as dementia will force her. If there is clinical trial, it is suitable for this patient. Drugs such as BTK inhibitors, e.g. ibrutinib has shown promising results. It may be combined with checkpoint inhibitors. Regimen like Nivo-Ibrutinib may be an option. Another promosing results are coming with CAR-T cell therapies. PCNSL are also responsive to these immunotherapies

  • Nov 23, 2024

    Pending Moderator approval.
    Delete

Further Reading

Recently Updated